Medtronic Dodges Two Of Three Claims In Pain-Pump Suit
Executive Summary
An Indiana federal judge axed two components of a patient’s lawsuit against Medtronic, while allowing a manufacturing defect complaint to move forward.
You may also be interested in...
Medtronic’s SynchroMed II Infusion Pain Treatment Proves Cost-Effective In Study
A new cost-effectiveness study shows cancer patients using targeted drug delivery with Medtronic’s SynchroMed II infusion system and conventional medical management incur lower overall health care costs than patients using conventional medical management alone.
SynchroMed brings no pain relief for Medtronic
Medtronic has agreed to the US FDA’s demands to stop making and distributing the SynchroMed II implantable infusion pumps, except in limited circumstances, until the company corrects quality system violations identified by the agency.
News We’re Watching: Lung Preservation System Goes National, De Novo For MMI, Brazil’s ANVISA To Recognize Overseas Approvals
This week, Paragonix announced that its BAROguard lung preservation system is now available throughout the US; Brazil planned to leverage some foreign device approvals; Medical Microinstruments’ Symani Surgical System won de novo clearance; and the FDA updated its safety warnings for Essure and certain plastic syringes.